Novavax says its COVID vaccine gets India authorisation for teens

Novavax Inc on Tuesday said its COVID-19 vaccine has received emergency use permission from the Drugs Controller General of India for children aged 12 to 17 years.

Authorization for Age Group is a global first for the vaccine, which is manufactured and marketed in India by the Serum Institute of India under the brand name Covovax.

Novavax said last month that its vaccine was 80% effective against COVID-19 in a late-stage trial of the shot in 2,247 adolescents aged 12 to 17 years.

The company on Tuesday said its vaccine produced an immune response in the same age group in a mid-to-late study involving 460 Indian adolescents.

Covovax is the fourth COVID-19 vaccine to be authorized for adolescents aged 12 years and above in India after Biologics E’s Corbevax, Zydus Cadila’s ZyCoV-D and Bharat Biotech’s Covaxin.

India, which had so far been vaccinating children aged 15 years and above, last week began administering doses of the biological E K Corbevax to children aged 12 to 14 years.

The country’s drug regulator in December authorized Novavax’s COVID-19 vaccine for people 18 years of age and older.

Zeen is a next generation WordPress theme. It’s powerful, beautifully designed and comes with everything you need to engage your visitors and increase conversions.

Subscribe to our newsletters
If you have any questions or comments, please don't hesitate to contact us.